Terms: = Pancreatic cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Treatment
14 results:
1. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).
Mahalingam D; Chen S; Xie P; Loghmani H; Heineman T; Kalyan A; Kircher S; Helenowski IB; Mi X; Maurer V; Coffey M; Mulcahy M; Benson A; Zhang B
Br J Cancer; 2023 Sep; 129(5):782-790. PubMed ID: 37443348
[TBL] [Abstract] [Full Text] [Related]
2. Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial.
Lin Q; Zheng S; Yu X; Chen M; Zhou Y; Zhou Q; Hu C; Gu J; Xu Z; Wang L; Liu Y; Liu Q; Wang M; Li G; Cheng H; Zhou D; Liu G; Fu Z; Long Y; Li Y; Wang W; Qin R; Li Z; Chen R
Cancer Commun (Lond); 2023 Feb; 43(2):257-275. PubMed ID: 36579790
[TBL] [Abstract] [Full Text] [Related]
3. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Széles Á; Fazekas T; Váncsa S; Váradi M; Kovács PT; Krafft U; Grünwald V; Hadaschik B; Csizmarik A; Hegyi P; Váradi A; Nyirády P; Szarvas T
Cancer Immunol Immunother; 2023 May; 72(5):1061-1073. PubMed ID: 36385210
[TBL] [Abstract] [Full Text] [Related]
4. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma.
Na BG; Kim YK; Hwang S; Lee KJ; Park GC; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yang H; Yoon YI; Tak E; Park YH; Lee SG
Medicine (Baltimore); 2021 Apr; 100(17):e25640. PubMed ID: 33907121
[TBL] [Abstract] [Full Text] [Related]
5. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C; Hagege A; Borchiellini D; Thamphya B; Rastoin O; Ambrosetti D; Iovanna J; Rioux-Leclercq N; Porta C; Negrier S; Ferrero JM; Chamorey E; Pagès G; Dufies M
Oncoimmunology; 2020 Nov; 9(1):1846901. PubMed ID: 33299657
[TBL] [Abstract] [Full Text] [Related]
6. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract] [Full Text] [Related]
7. Comparative Effectiveness of Pylorus-Preserving Versus Standard pancreaticoduodenectomy in Clinical Practice.
Calderon E; Day RW; Stucky CC; Gray RJ; Pockaj BA; Chang YH; Wasif N
Pancreas; 2020 Apr; 49(4):568-573. PubMed ID: 32282771
[TBL] [Abstract] [Full Text] [Related]
8. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
[TBL] [Abstract] [Full Text] [Related]
9. Human Surfactant Protein D Suppresses Epithelial-to-Mesenchymal Transition in pancreatic cancer Cells by Downregulating TGF-β.
Kaur A; Riaz MS; Singh SK; Kishore U
Front Immunol; 2018; 9():1844. PubMed ID: 30158928
[TBL] [Abstract] [Full Text] [Related]
10. A Recombinant Fragment of Human Surfactant Protein D induces Apoptosis in pancreatic cancer Cell Lines
Kaur A; Riaz MS; Murugaiah V; Varghese PM; Singh SK; Kishore U
Front Immunol; 2018; 9():1126. PubMed ID: 29915574
[TBL] [Abstract] [Full Text] [Related]
11. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
12. Outcomes of pancreaticoduodenectomy for pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?
Thiels CA; Bergquist JR; Laan DV; Croome KP; Smoot RL; Nagorney DM; Thompson GB; Kendrick ML; Farnell MB; Truty MJ
J Gastrointest Surg; 2016 May; 20(5):891-8. PubMed ID: 26925796
[TBL] [Abstract] [Full Text] [Related]
13. Troxacitabine: BCH 4556, spd 758, Troxatyl.
Adis International Ltd
Drugs R D; 2003; 4(4):264-8. PubMed ID: 12848594
[TBL] [Abstract] [Full Text] [Related]
14. Results of pancreaticoduodenectomy for pancreatic cancer: extended versus standard procedure.
Iacono C; Accordini S; Bortolasi L; Facci E; Zamboni G; Montresor E; Marinello PD; Serio G
World J Surg; 2002 Nov; 26(11):1309-14. PubMed ID: 12297922
[TBL] [Abstract] [Full Text] [Related]
